Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jun;53(6):545-51.
doi: 10.1007/s40262-014-0133-6.

Pharmacokinetics of indomethacin in pregnancy

Erik Rytting  1 , Tatiana N Nanovskaya, Xiaoming Wang, Daria I Vernikovskaya, Shannon M Clark, Marlo Cochran, Susan M Abdel-Rahman, Raman Venkataramanan, Steve N Caritis, Gary D V Hankins, Mahmoud S Ahmed
Affiliations
Clinical Trial

Pharmacokinetics of indomethacin in pregnancy

Erik Rytting et al. Clin Pharmacokinet. 2014 Jun.

Abstract

Background and objectives: Although indomethacin has been widely used for the treatment of preterm labor over the past 40 years, there are few reports regarding its pharmacokinetics in pregnant women.

Methods: This opportunistic study assessed the steady-state pharmacokinetics of indomethacin in pregnant subjects to whom an oral dose of 25 mg every 6 h was prescribed. Indomethacin concentrations in plasma and urine were analyzed by a validated high-performance liquid chromatography method with mass spectrometric detection.

Results: The mean area under the plasma concentration versus time curve at steady state (AUCss) was 1.91 ± 0.53 μg·h/mL, mean peak plasma concentration (C max) was 1.02 ± 0.49 μg/mL, and mean time to reach C max (t max) was 1.3 ± 0.7 h. The mean apparent clearance at steady state was 14.5 ± 5.5 L/h, which is higher than the apparent clearance reported in the literature for non-pregnant subjects. Indomethacin crosses the placenta; the mean fetal/maternal ratio from five sets of cord blood samples collected at delivery was 4.0 ± 1.1.

Conclusions: Further studies are needed to determine whether any dose adjustments are necessary as a result of the increased clearance of indomethacin during pregnancy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean steady-state plasma concentration versus time profile for 25 pregnant subjects receiving 25-mg oral doses of indomethacin every 6 h. Error bars represent the standard deviation
Fig. 2
Fig. 2
Comparison of cord blood and maternal concentrations of indomethacin at the time of delivery from five mother-child pairs. a Concentrations of indomethacin in maternal and cord blood versus the time between the last dose of indomethacin and delivery. b Cord blood indomethacin concentrations (z axis) versus the interval between the last dose and delivery (y axis) and the number of consecutive days of indomethacin dosing prior to delivery (x axis)
See this image and copyright information in PMC

References

    1. Gamissans O, Balasch J. Prostaglandin synthetase inhibitors in the treatment of preterm birth. In: Fuchs A-R, Stubblefield PG, Fuchs F, editors. Preterm birth: causes, prevention, and management. 2nd ed. McGraw-Hill; New York: 1993. pp. 309–32.
    1. Zuckerman H, Shalev E, Gilad G, et al. Further study of the inhibition of premature labor by indomethacin. Part II: double-blind study. J Perinatal Med. 1984;12:25–9. - PubMed
    1. Zuckerman H, Reiss U, Rubinstein I. Inhibition of human premature labor by indomethacin. Obst Gynecol. 1974;44:787–92. - PubMed
    1. Wiqvist N. Endogenous prostaglandins in normal pregnancy and labor. Pharmacol Ther B. 1975;1:297–310. - PubMed
    1. Rane A, Oelz O, Frolich JC, et al. Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther. 1978;23:658–68. - PubMed

Publication types